Literature DB >> 8201343

Idiopathic AA amyloidosis manifested by autonomic neuropathy, vestibulocochleopathy, and lattice corneal dystrophy.

I Tsunoda1, H Awano, H Kayama, T Tsukamoto, S Ueno, T Fujiwara, M Watanabe, T Yamamoto.   

Abstract

A 69-year-old Japanese woman with non-familial amyloidosis had polyneuropathy and profound autonomic neuropathy, and kappa chain monoclonal gammopathy. Immunohistopathological examination showed protein AA and protein AP in the amyloid deposits. She showed involvement of the vestibulocochlear nerve and lattice dystrophy of the cornea. Vestibulocochleopathy and corneal lattice dystrophy have been reported in familial amyloid polyneuropathy type IV, Finnish type, but never in non-familial amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201343      PMCID: PMC1072934          DOI: 10.1136/jnnp.57.5.635

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome.

Authors:  T J MUCKLE
Journal:  Q J Med       Date:  1962-04

2.  Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin.

Authors:  M Haltia; J Ghiso; F Prelli; G Gallo; S Kiuru; H Somer; J Palo; B Frangione
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

3.  Histopathological findings of familial amyloidosis with cranial neuropathy as principal manifestation. Report on three cases.

Authors:  J Meretoja; L Teppo
Journal:  Acta Pathol Microbiol Scand A       Date:  1971

4.  Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer.

Authors:  M W Van Allen; J A Frohlich; J R Davis
Journal:  Neurology       Date:  1969-01       Impact factor: 9.910

5.  [Familial primary amyloidosis with vitreous opacities and cognition disorder].

Authors:  M Okayama; I Goto; T Tanaka; T Omae
Journal:  Rinsho Shinkeigaku       Date:  1974-03

6.  Involvement of the autonomous nervous system in primary and secondary amyloidosis.

Authors:  C Nordborg; K Kristensson; Y Olsson; P Sourander
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

7.  Familial oculoleptomeningeal amyloidosis.

Authors:  H Goren; M C Steinberg; G H Farboody
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

8.  Finnish hereditary amyloidosis. Amino acid sequence homology between the amyloid fibril protein and human plasma gelsoline.

Authors:  C P Maury; K Alli; M Baumann
Journal:  FEBS Lett       Date:  1990-01-15       Impact factor: 4.124

9.  Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of this disease.

Authors:  J R Wright; E Calkins; R L Humphrey
Journal:  Lab Invest       Date:  1977-03       Impact factor: 5.662

10.  AA protein in a case of "primary" or "idiopathic" amyloidosis.

Authors:  M Pras; J Zaretzky; B Frangione; E C Franklin
Journal:  Am J Med       Date:  1980-02       Impact factor: 4.965

View more
  4 in total

Review 1.  Amyloid neuropathies.

Authors:  Susan C Shin; Jessica Robinson-Papp
Journal:  Mt Sinai J Med       Date:  2012 Nov-Dec

2.  Lactoferrin Glu561Asp facilitates secondary amyloidosis in the cornea.

Authors:  K Araki-Sasaki; Y Ando; M Nakamura; K Kitagawa; S Ikemizu; T Kawaji; T Yamashita; M Ueda; K Hirano; M Yamada; K Matsumoto; S Kinoshita; H Tanihara
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

3.  Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family.

Authors:  H S Stewart; R Parveen; A E Ridgway; R Bonshek; G C Black
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

4.  Classic lattice corneal dystrophy associated with monoclonal gammopathy after exclusion of a TGFBI mutation.

Authors:  Khairidzan M Kamal; Sylvia A Rayner; Michael C Chen; Anthony J Aldave
Journal:  Cornea       Date:  2009-01       Impact factor: 2.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.